Abbott Laboratories Corporation

Abbott Gmbh & Co Kg

Basf Aktiengesellschaft

Abbvie Deutschland Gmbh and Co Kg

Abbvie Inc.

Karsten M Wicke

Liliane Unger

Karla Drescher

Andreas Haupt

Hans-J&uuml;rgen Teschendorf

Dorothea Starck

Gerd Steiner

Alfred Bach

Frauke Pohlki

Franz Emling

Min Zhang

Udo Lange

Ana Lucia Relo

Uta Dullweber

Wilfried Martin Braje

Sean Colm Turner

Mario Mezler

Hans-Jurgen Teschendorf

Beate Hellendahl

Annegret Lansky

Anton Bespalov

Matthias Mayrer

Wolfgang Wernet

Gisela Backfisch

Rainer Munschauer

Ana-Lucia Relo

Siegfried Bialojan

Barbara Vogg

Juergen Delzer

Francisco-Javier Garcia-Ladona

Wilfried Lubisch

Hans-J&ouml;rg Treiber

Jürgen Dinges

Stefan Blank

Robert Van Waterschoot

Martin Winn

Bryan K Sorensen

Vince S Yeh

Jyoti R Patel

Hong Yong

James T Link

Jeffrey J Rohde

Marina Pliushchev

Hwan-soo Jae

Qi Shuai

Yanbin Lao

Dariusz Wodka

David J Madar

Michael E Brune

Jurgen Dinges

Peer Jacobson

Jiahong Wang

Ravi Kurukulasuriya

Lynne E Rueter

Kaitlin E Browman

R Scott Bitner

Xavier Garcia-Ladona

Wilfried Hornberger

Andreas Kling

Helmut Mack

Berthold Behl

Hervé Geneste

Achim Moeller

Martin Schmidt

Reinhold Mueller

Yixian Chen

Andrea Hager-Wernet, Legal Representative

Barbara Neumann-Schultz

Margaretha Bakker

Beatrice Rendenbach-Muller

Alfred Hahn, Legal Representative

Ana Lucia Jongen-Relo

Kurt Schellhaas

Sharon Cheetham

Frank Kerrrigan

Scott Mittelstadt

Thomas Schultz

Yixian Long

Theophile-Marie Le Bris

Ana Relo

The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HTreceptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HTreceptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HTreceptor.

[object Object]

A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-&#x3b2;-hydroxysteroid dehydrogenase Type 1 enzyme activity.

Treatment of central nervous system disorders

The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. In formula I, the variables have the following meanings:

Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor

The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor.

The present invention relates to benzenesulfonyl or sulfonamide compounds of formulae IA and IB wherein the variables have the meanings given in the claims and the description, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating diseases that respond to modulation of the serotonin 5-HTreceptor.

The present invention relates to N-Phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds of formula I wherein the variables have the meanings given in the claims and the description, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating diseases that respond to modulation of the serotonin 5-HTreceptor.

The present invention relates to compounds of formula (I) wherein A is C-C-alkyl, C-C-haloalkyl, C-C-hydroxyalkyl, C-C-alkenyl, C-C-halo-alkenyl, C-C-cycloalkyl, aryl-C-C-alkyl, aryl-C-C-alkenyl, aryl or hetaryl;is a single or double bond; Xand Xare N, CR, NRor CRR; R, Rand Rare H, halogen, CN, NO, C-C-alkyl, C-C-alkoxy, C-C-alkylcarbonyl, etc. or two geminal radicals Rand Rtogether with the carbon atom to which they are bound may form a carbonyl group or a 3- to 6-membered carbocyclic or heterocyclic spiro-annulated ring; Ris hydrogen, C-C-alkyl, C-C-alkylcarbonyl, C-C-haloalkyl, etc.; or two vicinal radicals R, R, Ror Rtogether with Xand Xform a five- or six-membered carbocyclic or heterocyclic fused ring; Y, Yand Yare N or CR; Ris H, halogen, CN, NO, C-C-alkyl, C-C-alkoxy, C-C-alkylcarbonyl, C-C-haloalkyl, etc.; wherein a maximum of 3 of the radicals X, X, Y, Yand Yare selected from NRand N; Ris hydrogen, C-C-alkyl, C-C-hydroxyalkyl, C-C-haloalkyl, etc.; Ris C-C-alkyl or C-C-haloalkyl; n is 0, 1 or 2; physiologically tolerated acid addition salts and the N-oxides thereof, pharmaceutical composition comprising them, a method for treating medical disorders selected from diseases of the central nervous system, addiction diseases or obesity, said method comprising administering an effective amount of such compounds to a subject in need and the use of such a compound for preparing a pharmaceutical compositions.

The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HTreceptor. In formula (I) R is a moiety of the formula (R) wherein * indicates the binding site to the quinolinyl radical and wherein A, B, X', Y, Q, R, R, R, R, R, m, n, p, q, R, R, X and Ar are as defined in claim. 

The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I' and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HTreceptor. 

The present invention relates to N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating diseases that respond to modulation of the serotonin 5-HTreceptor.

N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor

The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HTreceptor. In formula (I) R is a moiety of the formula (R) wherein * indicates the binding site to the quinolinyl radical and wherein A, B, X', Y, Q, R, R, R, R, R, m, n, p, q, R, R, X and Ar are as defined in claim 1. 

The present invention relates to novel quinoline compounds. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HTreceptor. wherein 

Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor

Growing community of inventors

Altrip, Germany

Karsten M Wicke